PRF1 and urinary bladder carcinoma: In bladder cancer, TRMs can be activated by anti-CD3, anti-CD28, and IL-15 stimulation, leading to proliferation and increased T-bet, perforin, and granzyme B expression, particularly in the PD-1+ subset (205).